Virtu Financial LLC Takes Position in Health Catalyst, Inc. (NASDAQ:HCAT)

Virtu Financial LLC bought a new position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 15,497 shares of the company’s stock, valued at approximately $110,000.

Other institutional investors have also added to or reduced their stakes in the company. Fred Alger Management LLC acquired a new position in shares of Health Catalyst during the 3rd quarter worth about $6,858,000. Point72 Asset Management L.P. increased its position in Health Catalyst by 69.4% during the third quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock worth $4,208,000 after buying an additional 211,805 shares during the last quarter. Impax Asset Management Group plc raised its stake in Health Catalyst by 7.7% in the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock valued at $19,442,000 after buying an additional 195,525 shares during the period. Geode Capital Management LLC lifted its position in shares of Health Catalyst by 4.9% in the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock valued at $11,749,000 after buying an additional 66,896 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Health Catalyst by 2.5% during the 3rd quarter. State Street Corp now owns 1,163,754 shares of the company’s stock worth $9,473,000 after acquiring an additional 28,251 shares during the last quarter. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HCAT has been the subject of a number of research analyst reports. Stephens reduced their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, March 6th. Citigroup decreased their price target on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Stifel Nicolaus reduced their price objective on Health Catalyst from $10.00 to $5.00 and set a “hold” rating for the company in a report on Thursday, February 27th. Piper Sandler lowered their target price on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 11th. Finally, Canaccord Genuity Group reduced their price target on Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, January 21st. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.27.

Health Catalyst Price Performance

HCAT stock opened at $4.55 on Monday. The company’s 50-day moving average price is $5.03 and its two-hundred day moving average price is $6.85. Health Catalyst, Inc. has a 12 month low of $3.76 and a 12 month high of $9.24. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a market cap of $319.46 million, a P/E ratio of -3.37 and a beta of 1.41.

Insider Activity at Health Catalyst

In related news, General Counsel Benjamin Landry sold 13,827 shares of Health Catalyst stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $4.55, for a total transaction of $62,912.85. Following the sale, the general counsel now directly owns 160,437 shares of the company’s stock, valued at approximately $729,988.35. The trade was a 7.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $7.51, for a total transaction of $39,119.59. Following the completion of the transaction, the chief operating officer now directly owns 91,253 shares of the company’s stock, valued at approximately $685,310.03. The trade was a 5.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 56,530 shares of company stock valued at $299,572 over the last three months. 2.50% of the stock is owned by insiders.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.